Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vorsetuzumab mafodotin
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Vorsetuzumab mafodotin is an antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody (vorsetuzumab) targeting the extracellular domain of the human CD70 molecule, conjugated to the cytotoxic agent monomethyl auristatin F (MMAF), specifically as a non-cleavable linker. The drug was designed for targeted cancer therapy, particularly in CD70-expressing malignancies such as renal cell carcinoma and non-Hodgkin's lymphoma. Upon binding to CD70 on tumor cells, the ADC is internalized and releases MMAF intracellularly, which inhibits tubulin polymerization, leading to mitotic arrest and apoptosis of cancer cells. Vorsetuzumab mafodotin was developed by Seattle Genetics (now Seagen, a subsidiary of Pfizer). Clinical development reached phase 1 trials but was discontinued for both renal cell carcinoma and non-Hodgkin's lymphoma[1][2][4][5][7].
- Other names
- vorsetuzumab mafodotinSGN-75SGN75SGN 75
02
Targets
CD70 (Cluster of Differentiation 70)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on vorsetuzumab mafodotin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vorsetuzumab mafodotin.